Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$14.94 USD

14.94
4,916,268

+1.09 (7.87%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $14.83 -0.11 (-0.74%) 7:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tirthankar Chakraborty headshot

2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks

by Tirthankar Chakraborty

As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.

Sanghamitra Saha headshot

Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

by Sanghamitra Saha

Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

Ritujay Ghosh headshot

Coronavirus Vaccine Development Gathers Steam: 4 Winners

by Ritujay Ghosh

Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

Jeremy Mullin headshot

S&P Set to Open Above 3000

by Jeremy Mullin

Bulls start the week trying to break the 200-day moving average.

Sweta Jaiswal, FRM headshot

Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

by Sweta Jaiswal, FRM

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

Sanghamitra Saha headshot

Wining ETF Areas of Last Week

by Sanghamitra Saha

Though last week was not upbeat for Wall Street, these ETFs breezed past Wall Street.

Sanghamitra Saha headshot

Leveraged ETFs of Last Week

by Sanghamitra Saha

These leveraged ETFs were outperformers last week.

Is Novavax (NVAX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (NVAX) Outperforming Other Medical Stocks This Year?

Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine

by Zacks Equity Research

Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.

Sweta Jaiswal, FRM headshot

Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain

by Sweta Jaiswal, FRM

Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.

Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of 13.43% and -3.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Novavax (NVAX)

by Zacks Equity Research

Novavax (NVAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Emergent (EBS) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed at $18.13 in the latest trading session, marking a -1.52% move from the prior day.

Novavax (NVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax

3 Stocks to Benefit From Race to Develop Coronavirus Vaccines

by Zacks Equity Research

Pharmaceutical companies and scientists are relentlessly working on developing coronavirus vaccines and the progress in trails has helped stocks to rally.

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

During Novavax's (NVAX) upcoming Q1 earnings call, investor focus will be on the company's progress with its seasonal influenza vaccine candidate, NanoFlu, and the COVID-19 vaccine candidate.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $21.37, marking a -0.74% move from the previous day.

Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates

by Zacks Equity Research

Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.

Ritujay Ghosh headshot

Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

by Ritujay Ghosh

If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $17.05, marking a -0.76% move from the previous day.

Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate

by Zacks Equity Research

Novovax (NVAX) announces plans to initiate clinical study to evaluate its coronavirus vaccine candidate in May, weeks ahead of schedule.

Sweta Jaiswal, FRM headshot

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

by Sweta Jaiswal, FRM

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Implied Volatility Surging for Novavax (NVAX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.